FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals
Teva Pharmaceuticals has received approval for its Abbreviated New Drug Application (ANDA211187) for Macitentan.
Asset / Drug
Drug and asset intelligence for Macitentan with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.